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The Role of Molecular Imaging in
Personalised Healthcare
Jason P. Holland*
Abstract: Functional molecular imaging provides a unique perspective on a disease. Methods including positron-
emission tomography and magnetic resonance imaging allow us to interrogate spatial and temporal changes in
biomarkers as well as probe the underlying biochemistry. When imaging is combined with molecular diagnostic
tools, opportunities arise for measuring aberrant cellular signalling pathways with unprecedented detail. This
brief commentary illustrates how radiotracers and nuclear imaging methods are being developed to monitor drug
efficacy and simultaneously support the goal of personalised healthcare.
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Introduction
Recent years have witnessed an in-
creased scientific, clinical and political
emphasis on delivering measureable ben-
efits to individual patients, and to overall
population health, through ‘personalised
medicine’ (PM). Unprecedented advances
in various ‘-omic’ technologies have led to
exponential growth in our understanding
of the pathobiology of disease.
[1]
In turn, a
deeper knowledge of disease mechanisms
provides inspiration for developing inno-
vative diagnostic and therapeutic solutions
that promise to improve treatment efficacy
and patient outcomes across medicine. In
this setting PM, which is often considered
synonymous with other terms including
‘precision medicine’, ‘targeted medicine’,
or ‘stratified medicine’, provides the ide-
ological framework around which many
of the latest medical advances are being
shaped.
It is important to note that PM is not a
new concept. Hippocrates (c. 460 BC – c.
370 BC) famously postulated that, “It is far
more important to know what person the
disease has than what disease the person
has.”
[2]
Many clinicians would also argue
that medicine has always been ‘person-
alised’ – doctors treat patients on an in-
dividual basis and thus, at the point care,
medicine is inherently personal. However,
modern PM is evolving rapidly and goes
beyond simply recognising patients as in-
dividuals. Perhaps the most scientifically
rigorous definition of PM was provided
by the National Institute of Health (NIH)
which stated that PM, “… uses information
about a person’s genes, proteins and envi-
ronment to prevent, diagnose and treat dis-
ease.”
[3]
A more approachable definition
that captures the goals of PMwas provided
by the European Alliance for Personalised
Medicine which noted that PM is about,
“The right prevention and treatment for the
right patient at the right time.”
[4]
Beyond
these statements lies the current concept of
PM which is to integrate vast amounts of
patient-specific and population-based data
with the aim of providing a more accurate
and complete picture of not only the cur-
rent status but the entire disease lifecycle
(Fig. 1). In this regard, PM is a dynam-
ic process. It facilitates informed deci-
sion-making, helping clinicians select the
most appropriate therapeutic regimen at a
given time, and simultaneously provides
accurate, active monitoring to help tailor
the treatment toward the most effective
solution for a single patient.
Data integration lies at the heart of PM.
Data sources include traditional medical
records and family histories, through to
population-based information on disease
aetiology and epidemiology. During con-
sultation and diagnosis, these physiologic
data are usually combined with a range of
standard in vitro diagnostic (IVDx) assays
including biomarker measurements from
serum or biopsy studies, and histological
information from tissue samples that link
disease symptoms with the underlying
biochemistry. Nowadays, the latest ‘-om-
ic’ technologies provide increasingly de-
tailed information on disease status at all
levels from single-cell genetics through to
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and temporal information about the way in
which the body interacts with a drug (PK)
and how the drug affects the biochemistry
of the recipient (PD). Imaging methods in-
cluding PET, SPECT and functional MRI
can be used as a companion diagnostic
(CDx) for staging a disease/lesion, as a
prognostic indicator of disease progres-
sion, and for stratifying patients by pre-
dicting likely response to therapy. Further,
imaging provides a non-invasive way of
monitoring the outcome of therapy.
The quality of information provided
by imaging is highly dependent on i) the
choice of imaging biomarker, and ii) the
physical, biochemical, and pharmacolog-
ical characteristics of the imaging agent.
Serum Biomarkers versus Imaging
To highlight the power of imaging, con-
sider a patient undergoing therapy to treat a
disseminated disease (Fig. 2). After treat-
ment, responders typically present with an
overall decreased disease burden includ-
ing fewer and/or smaller lesions, with a
lower grade or less aggressive phenotype
(green). In the ideal case, responders are
completely disease-free after treatment.
Non-responders show either no change in
disease status or may exhibit higher dis-
ease burden with an increased number of
lesions, increased lesion size, or transfor-
mation to a more aggressive phenotype
(red). Partial responders, including patients
who develop subsequent resistance to the
therapy or those who relapse, can exhibit a
heterogeneous response. This can include
complete loss or presentation of new dis-
ease foci, as well as lesions that decrease
in size and/or become less aggressive, dis-
Molecular Imaging and
Personalised Medicine
Molecular imaging plays a vital role
in PM.
[7–9]
Images are inherently personal
and at a basic level can assess the location,
size and severity of a lesion. Imaging da-
ta can also be recorded (and sometimes
processed) in real-time to provide spatial
tissue and whole organisms phenotypes.
Categorised as a broad spectrum of molec-
ular diagnostics (MDx), these new technol-
ogies span the fields of genomics (DNA),
transcriptomics (RNA), and epigenetics
[5]
(Me-DNA, methylomics), through to pro-
teomics and metabolomics.
[1]
Anatomic
imaging in the form of computed tomog-
raphy (CT) or magnetic resonance imaging
(MRI), as well as functional molecular im-
aging (MI) using single-photon emission
computed tomography (SPECT), positron
emission tomography (PET) and various
optical methods, are vital tools that pro-
vide a visual link between changes at the
molecular, tissue and organism levels.
[6]
Collectively, these diagnostic data offer
an improved understanding of the phar-
macokinetic (PK) and pharmacodynamic
(PD) profiles of drug response. Thus, by
combining IVDx, MDx and imaging with
pharmacogenomics, it is (theoretically)
possible to monitor the entire course of
therapy and to respond actively in a way
that leads to the optimum outcome for a
patient.
PM, and indeed molecular imaging and
radiochemistry, are too broad to be covered
in detail in this commentary. Therefore, the
following sections focus on the role that
functional molecular imaging plays in ad-
vancing the practical application of PM in
the clinic. Emphasis is placed on illustrat-
ing the use of PET for detecting changes in
oncogenic signalling pathways in various
cancers.
Fig. 1. Illustration of the key components that constitute practical application of PM. The concept
is to integrate clinical data from many sources including medical records, patient histories,
population studies, and in vitro diagnostic (IVDx) tools, with the latest information from molecular
diagnostics (MDx) and imaging to provide clinicians with the most accurate pharmacogenomic
picture for tailoring individual treatment.
Fig. 2. Illustration of the potential range of response for a patient undergoing therapy to treat a
disseminated disease. Partial responders exhibit a heterogeneous response to therapy which
may include lesions that decrease in size and/or become less aggressive (green), lesions that
display no change (yellow), lesions that increasing in size and/or transform to a more aggressive
phenotype (red), complete loss and/or presentation of new disease foci.
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biomarker (usually chosen as an overex-
pressed, upstream component of a signal-
ling pathway) changes during the disease
lifespan or treatment, we can potentially
image and correlate this change with alter-
ations in tissue biochemistry and drug ef-
ficacy. Inhibition of a particular signalling
pathway can alter DNA transcription and
protein expression which, via positive or
negative feedback loops, can modulate bi-
omarker concentration. In this context, the
predictive biomarker also doubles as a PD
biomarker. As a practical example, PET
imaging of human epidermal growth factor
receptor 2 (HER2/neu) has been used as a
PD biomarker correlating with the efficacy
of different heat shock protein 90 (HSP90)
inhibitors in breast cancer models.
[17,22]
Alternatively, PD biomarkers can be
selected from proteins that are expressed
downstream of a particular signalling
pathway. The key criterion is that the ex-
pression level of the downstream PD bio-
marker should correlate with the parameter
of interest. These biomarkers can be used
as surrogates for detecting changes in the
activation or inhibition of enzymes, signal
transduction, or transcription factor activi-
ty. Similarly, PD biomarkers can correlate
with broader cellular processes like growth
and proliferation, survival, or apoptosis,
etc. Essentially, the only prerequisites for
surrogate imaging of PD biomarkers are, i)
developing specific and sensitive imaging
agents that allow for quantitative detec-
tion, and ii) understanding the biochemi-
cal mechanisms of how target expression
correlates with the parameter of interest.
If these conditions are met, then imaging
data can provide a sensitive, lesion-specif-
ic readout of whether the drug has hit the
target and if the dose administered was suf-
ficient to elicit a pharmacologic response.
Imaging PD biomarkers can also show
early onset of resistance thereby allowing
clinicians to adapt the treatment regimen
accordingly.
non-polyposis colorectal cancer) which
is caused by faults in the MLH1, MSH2,
MSH6 and PMS2 genes and correlates
with increased risk of developing several
cancers including (among others) ovarian,
uterus endometrial, colorectal, gastric and
renal.
Predictive biomarkers indicate the
likely response of a lesion toward therapy.
For example, it is estimated that between
20–30% of breast cancer patients overex-
press the human epidermal growth factor
receptor 2 (HER2).
[15,16]
Imaging trials
using
89
Zr-trastuzumab
[17]
and other PET
radiotracers show promise for identifying
patients that display elevated HER2 ex-
pression and may potentially benefit from
immunotherapy using Herceptin
®
(trastu-
zumab) or Perjeta
®
(pertuzumab).
[18,19]
In 2011, Yeh et al. reported an elegant
example of developing a PET radiotrac-
er, [
18
F]F-PEG6-IPQA, for detecting the
L858R/T790M dual mutant epidermal
growth factor receptor (EGFR) in non-
small cell lung cancer (NSCLC).
[20]
The
L858R/T790M dual mutation is located in
EGFR kinase domain and confers resist-
ance to EGFR inhibitors (i.e. gefitinib).
At the same time, the T790M mutation
prevents the irreversible binding of [
18
F]
F-PEG6-IPQA to EGFR. Thus, PET im-
aging with [
18
F]F-PEG6-IPQA can po-
tentially predict response or resistance to
anti-EGFR therapies.
A portion of our work is dedicated
toward the development of radiotracers
that image changes in oncogenic signal-
ling in various cancers.
[21]
To achieve this,
we target PD biomarkers.
[13]
A schematic
representation of cellular signalling, and
possible sources of targets for radiotracer
imaging is shown in Fig. 4. In general, PD
biomarkers are usually proteins that show
differential expression during disease
progression and/or therapeutic interven-
tion. Targets can be selected from either
upstream or downstream components of
the signalling pathway of interest. For ex-
ample, if the concentration of a predictive
play no change, increasing in size and/or
transform to a more aggressive phenotype.
Concentration levels of serum bio-
markers are commonly assessed using a
range of IVDx tools. For example, blood
pool concentrations of prostate-specif-
ic antigen (PSA; kallikrein III) are com-
monly used as a risk factor for prostate
cancer (PCa). Although still experimen-
tal, PSA concentrations generally show
a positive correlation with PCa staging
(Gleason score).
[10,11]
PSA concentrations
below 4.0 ng/mL are considered normal.
Measurements between 4–10 ng/mL are
suspicious and these patients are usually
referred for additional testing. PSA val-
ues between 10–20 ng/mL indicate an
intermediate risk factor, whereas values
>20 ng/mL represent high risk and often
correlate with Gleason score ≥8. Consider
a patient that exhibits a partial response to
chemotherapy (e.g. using antiandrogens
like non-steroidal flutamide, nilutamide
or enzalutamide, etc.); hypothetically, in-
dividual tumour lesions that respond to
treatment could correlate with decreased
PSA expression. In contrast, lesions that
do not respond, grow and/or transform to
a more aggressive phenotype could corre-
late with either no change or elevated PSA
(Fig. 3). For partial responders that have
a heterogeneous disease burden, serum
biomarker measurements can be mislead-
ing. Put another way, it is impossible for
single measurement of a blood pool bio-
marker to discriminate between a patient
in which 100% of the tumours show a 50%
response, from a patient in which 50% of
the tumours show a 100% response. This
situation is where whole-body, non-inva-
sive molecular imaging presents an advan-
tage over classical IVDx assays.
Imaging Biomarkers
It should be noted that while overlap
exists between biomarkers used in IVDx,
MDx and imaging, in general, optimal im-
aging biomarkers do not necessarily have
the same characteristics as those used in
other experiments. Identification of new
‘imageable’ biomarkers is a priority in ba-
sic science and clinical research.
Biomarkers can usually be classified
as either prognostic, predictive or pharma-
codynamic based on the type of the infor-
mation that their detection provides.
[12,13]
Prognostic biomarkers indicate the risk
of disease or likelihood of progression.
For instance, many genomic mutations
can be considered as prognostic risk fac-
tors toward the development of different
cancers.
[14]
Examples include mutated
BRCA1 and BRCA2 genes in breast,
ovarian and prostate cancers, RB1 in ret-
inoblastoma, mutations in the Von Hippel-
Lindau (VHL) gene in renal cancers, or
Lynch syndrome (also called hereditary
Fig. 3. Schematic bar
chart presenting a
hypothetic change in
the concentration of
a serum biomarker
that exhibits a rapid
change and strong
positive correlation
with disease burden
and/or aggression
in non-responders
(red), responders
(green) and patients
that display partial
response to therapy
(blue).
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in comparison to the non-treated (No Tx)
vehicle control, PET signals in tumours de-
creased by ~35% in animals that received
supplementary testosterone. In contrast,
treatment with MDV3100 led to an ap-
proximate 80% increase in radiotracer ac-
cumulation. Subsequently, we developed
and translated the immuno-PET radiotrac-
er,
89
Zr-DFO-J591 for measuring PSMA
expression (Fig. 5B).
[24–26]
In combina-
tion with the well-established radiotrac-
er,
18
F-FDHT
[27]
(16β-
18
F-fluoro-5α-dihy-
drotestosterone; Fig. 5C), we are evaluat-
ing a novel molecular imaging algorithm
(Fig. 5D) for measuring AR expression,
drug binding and efficacy. In this proto-
col, baseline
18
F-FDHT PET can be used
to predict if a patient (or a specific lesion)
will respond to antiandrogen treatment.
During treatment, further
18
F-FDHT scans
canmonitor drug-target engagement. Here,
a high PET signal on a post-treatment
18
F-FDHT scan is potentially indicative
of either sub-optimal dosing, phenotypic
transformation or the onset of resistance
toward antiandrogens. Antiandrogen dose
can (theoretically) be adjusted based on
the imaging data. However, simply hitting
the target does not mean that the desired
pharmacologic response (i.e. inhibition of
the AR-signalling pathway) has occurred.
PET imaging of PSMA can be used as a
PD biomarker that correlates with AR-
signalling, allowing clinicians to address
the question, “Is the drug working?”. In
these PSMA scans, the inverse correla-
tion between AR-signalling and PSMA
expression means that a high PET signal
intensity suggests that the drug is work-
ing. In contrast, a low PET signal indicates
that the AR-pathway remains active. This
mechanism for monitoring antiandrogen
response has recently been studied in a pi-
lot human image using the small-molecule
radiotracer
68
Ga-PSMA-11.
[28]
Notably,
we have also extended the technology to
include
89
Zr-DFO-5A10 immuno-PET im-
aging of AR-signalling via measuring the
expression of tissue-localised PSA.
[21,29]
In practice, a molecular imaging al-
gorithm that involves multiple PET scans
acquired using two or more different ra-
diotracers is technically challenging.
However, as with IVDx tests, no single im-
age/radiotracer can be expected to provide
all the information required to characterise
disease status in full. Our ability to detect
and interpret temporal changes in several
biomarkers is crucial to the future of PM.
In this regard, imaging AR expression via
18
F-FDHT PET, and AR-signalling via
PSMA represents a positive step toward
multi-parametric imaging protocols.
Therefore, the goal was to develop a PET
imaging protocol that could be used to
measure both AR levels (in the sense of
a predictive biomarker for estimating re-
sponse to therapy and monitoring drug-tar-
get engagement) and AR activity using a
PD biomarker to measure if the drug con-
centration delivered to the target is suffi-
cient to elicit a pharmacologic response.
In preclinical work, Evans et al.
demonstrated that activation of AR signal-
ling by natural ligands including testoster-
one (Test.) or dihydrotestosterone (DHT)
leads to suppression of cellular surface
biomarker prostate-specific membrane an-
tigen (PSMA) expression.
[23]
Conversely,
AR-inhibition using antiandrogens includ-
ing MDV3100 (enzalutamide) increases
PSMA expression (Fig. 5A). Preclinical
immuno-PET imaging using an anti-
body-based radiotracer administered to
mouse models bearing subcutaneous, AR-
positive, human xenografts confirmed that,
Imaging Pharmacodynamic
Biomarkers in Prostate Cancer
This section highlights two examples
that show how surrogate imaging of PD
biomarkers is being used to monitor dis-
ease status and treatment in prostate cancer
(PCa).
Imaging Androgen-receptor
Signalling and Antiandrogen
Therapy in PCa
Together with colleagues at Memorial
Sloan-Kettering Cancer Centre in New
York, we are developing an imaging pro-
tocol for measuring response to antian-
drogen therapy in PCa patients (Fig. 5).
Androgen-receptor (AR) signalling is a
key driver of PCa. Prior to transformation
toward a castrate-resistant (or hormone
refractory) phenotype, antiandrogen ther-
apies (e.g. flutamide, enzalutamide, etc.)
have an increased likelihood of working.
Fig. 4. Schematic flow of information during intracellular signalling from ligand-receptor
interactions, messenger and transcription factor activation, regulation of DNA expression and
protein translation. Potential sources of ‘imageable’ predictive and PD biomarkers that can be
used in the development of radiotracers are highlighted with a radioactive symbol.
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Imaging MYC Transcription Factor
Activity
Studies have revealed that 30–70%
of PCa patients display loss of the PTEN
tumour suppressor gene and elevated sig-
nalling via PI3K/Akt.
[30]
Similarly, ~30%
of PCa patients are found to have a gain
in copy number and activity of the tran-
scription factor MYC.
[31]
These signalling
pathways play vital roles in cell survival,
growth, proliferation and metastasis.
[21,32]
Since the 1970s, many attempts to tar-
get MYC met with limited success, pri-
marily because transcription factors are in
low abundance and MYC lacks any recog-
nisable ligand binding sites as a basis for
drug discovery. However, in 2010 Bradner
and co-workers reported the structure and
activity of JQ1, a first-in-class inhibitor
of the bromodomain and extra-terminal
domain (BET) protein, BRD4 (Fig. 6).
[33]
BET proteins (like BRD4) regulate gene
expression by binding to acetylated his-
tones and alter chromatin structure. JQ1
inhibition of BRD4 (and potentially other
BET proteins [BRD2-4]) was found to in-
duce down-regulation of MYC transcrip-
tion via the loss of BRD4 at the MYC pro-
moter site.
[34]
Consequently, reduced levels
of MYC also led to reduced expression of
MYC target genes including the transferrin
receptor (CD71 or TRFC).
[31]
Recognising the central role of MYC
and PI3K/AKT signalling in various can-
cers, we developed
89
Zr-transferrin (
89
Zr-
Tf) to detect changes in these signalling
pathways via detection of downstream
TRFC (Fig. 7). Proof-of-concept stud-
ies using a transgenic mouse model that
displays high levels of MYC expression/
activity in the dorsolateral prostate demon-
strated that
89
Zr-Tf imaging of TRFC cor-
related with changes in MYC-signalling in
PCa.
[35]
In addition, we found that
89
Zr-Tf
can detect differences in PI3K signalling
in gliomas.
[36]
Collectively, these studies
provided convincing evidence that TRFC
can be used as a PD biomarker of MYC
and PI3K-signalling, and also suggested
that
89
Zr-Tf could be used to monitor ther-
apies that target these pathways. In 2016,
this hypothesis was confirmed by Doran et
al. who showed that
89
Zr-Tf imaging pro-
vides a diagnostic measure of JQ1 activity
in lymphoma.
[37]
Efforts are now underway
to translate this technology to the clinic.
Methods in PET Radiochemistry
This section provides a flavour of the
types of chemistry used in the synthesis
of PET radiotracers. The discussion is
restricted to
18
F and radiometal nuclides,
but it should be noted that work with
11
C,
13
N and
15
O are also active areas of PET
research.
[38]
A schematic showing the pro-
cess of positron (β
+
) emission and subse-
quent annihilation to give two antiparallel
γ-rays is shown in Fig. 8. Coincident detec-
tion of two 511 keV γ-rays is the physical
basis of PET imaging. However, the true
value of PET resides in our ability to syn-
thesise positron-emitting radiotracers that
bind to specific targets with high affinity.
Fluorine-18 Radiochemistry
The range of chemical reactions that
can be used to incorporate a radionuclide
into a molecule is very diverse.
[38]
Yet in
radiochemistry with PET nuclides such as
18
F (t
1/2
= 109.7 min) or radiometals like
64
Cu (t
1/2
= 12.7 h),
68
Ga (t
1/2
= 67.7min) and
89
Zr (t
1/2
= 78.41 h), limitations arise that
are not encountered in traditional non-radi-
Fig. 6. Structures
of BET inhibitors
JQ1 and I-BET151
(GSK1210151A).
Fig. 5. Imaging AR signalling and antiandrogen therapy in PCa. (A) Schematic of AR-signalling
in relation to inverse PSMA expression and proof-of-concept PET images showing the effects of
MDV3100 (Enzalutamide) on PET radiotracer uptake. (B) Structure of
89
Zr-DFO-J591. (C) Structure
of
18
F-FDHT. (D) A molecular imaging algorithm for measuring AR-inhibition and drug efficacy in
PCa patients.
A
B
D
C
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have been reported including Pd(iv)
[45]
and Ni(ii)
[46]
agents for ‘electrophilic’ la-
belling and copper-catalysed substitutions
using iodonium(iii) salts.
[47–49]
Studies
have also explored the potential of iodo-
nium(iii) ylide chemistry for nucleophilic
18
F-labelling of challenging drug-like syn-
thons containing electron-rich (deactivat-
ed) aromatic substrates.
[50–53]
Metal-based Radiochemistry
In many ways, the radiochemistry of
metal nuclides remains underdeveloped.
With few exceptions, production of met-
al-based radiotracers entails the use of
an organic chelating ligand.
[54,55]
For ex-
ample, the ubiquitous aza-macrocycles
DOTA and NOTA, as well as bicyclic
versions like CB-TE2A are useful for
complexing various nuclides including
64
Cu,
68
Ga,
177
Lu and
225
Ac, etc.; EDTA
and DTPA are powerful ligands for the
SPECT and Auger electron emitter
111
In,
and desferrioxamine B (DFO) is the ligand
of choice for complexing
89
Zr
4+
ions (Fig.
5B vide supra).
[39,55]
Typically, the chelate
is first conjugated to the biological vector
(through standard coupling reactions like
peptide bond synthesis, maleimido-chem-
istry or ‘click’-reactions, etc.), and then
after purification, the radiometal ion is in-
troduced in the final step.
[40]
State-of-the-
art research on radiometals is focused on
developing new radiochemical reactions,
accessing alternative nuclides (like the
positron-emitter
90
Nb, or alpha-emitters
223
Ra,
213
Bi and
225
Ac), and designing new
ligands with improved coordination prop-
erties, increased metal ion selectivity, and/
or increased stability in vivo.
Nanoparticles in Radiochemistry
and Imaging
As macromolecular scaffolds for de-
veloping drugs and MI agents, nanopar-
ticles offer unparalleled opportunities for
exploiting their chemical and structural
features. Nanoparticle characteristics in-
clude enhanced rigidity, controlled shape
and size, defined electromagnetic proper-
ties, high surface area, variable porosity,
resistance to metabolism in vivo, and tune-
able chemical reactivity at the surface, on
coatings and inside the particle core.
[56–64]
The majority of current methods for label-
ling nanoparticles derive from well-estab-
lished
18
F-labelling or radiometal chelation
chemistries (Fig. 10).
[65,66]
Available meth-
ods can be broadly classified as either sur-
face-based or coating-basedmodifications.
Briefly, surface modifications include
physisorption through electrostatic inter-
actions, direct chemisorption with discrete
chemical bond formation (c.f.As(iii)/As(v)
chemistry
[67]
), direct attachment of a radi-
olabelled species (e.g. –SCH
2
CH
2
CH
2
18
F),
and pre-surface modification with subse-
at the expense of performing time-con-
suming, multi-step reactions which com-
promise yields and reduce specific activi-
ties.
[40]
Use of bulky, lipophilic prosthetic
groups also incurs the risk of altering the
radiotracer properties (binding affinity,
specificity or PK/PD profiles, etc.) through
excessive modification. Recent advanc-
es in
18
F-radiochemistry include the use
of p-block elements as scaffolds such as
boron trifluorides,
[41]
silicon fluorides
[42,43]
or even metal-mediated ‘AlF’ chemistry
where
18
F reacts with Al
3+
ions, followed
by chelation using macrocyclic chelates
conjugated to a biological vector (pep-
tide or protein) to give the corresponding
‘Al
18
F’-complex.
[44]
Metal-based catalysts
for
18
F-labelling of substituted aromatics
oactive synthesis.
[39]
These challenges de-
rive from the radioactive decay properties
of the nuclide.
[39]
Considerations including
the half-life, particle energies and type of
emissions, radiolysis, specific activity,
available chemical forms of the nuclide,
and slow reaction kinetics at pico-molar
concentrations, often transpire as restric-
tions in the chemical methods that may be
utilised in radiosynthesis. To illustrate, af-
ter more than four decades of development,
synthesis of
18
F-radiotracers is dominated
by late-stage incorporation of the nuclide
using mainly one-step nucleophilic (aro-
matic S
N
Ar and aliphatic S
N
2) substitution
reactions (Fig. 9).
[38]
For molecules where
direct labelling is not practical, prosthetic
group methods can be used but typically
Fig. 7. Schematic
showing how PI3K/
AKT and BRD4/
MYC signalling
relates to changes
in expression of the
transferrin receptor
(CD71 or TRFC). PET
images demonstrate
proof-of-concept for
imaging changes in
MYC transcription
factor activity in a
transgenic mouse
model that displays
high levels of MYC
signalling in the
dorsolateral prostate.
Fig. 8. Schematic
showing the decay
of an
18
F nucleus
releasing the
daughter nuclide
18
O, a neutrino (υ
e
)
and a positron (β
+
).
Positron-electron
annihilation emits
two 511 keV γ-rays at
approximately 180°.
Coincident detection
of these two γ-rays
is the basis of PET
imaging.
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groups can bind to the magnetite crystal
core without using a chelate. Detailed stud-
ies on the mechanism of binding are under-
way and it is likely that metal ion affinity
is mediated via binding to oxides on the
surface of the ultra-small super paramag-
netic iron oxide (USPIO) core. The com-
bination of facile radiolabelling chemistry
with USPIO-based nanoparticles opens
the potential for developing multi-modal
agents for simultaneous imaging with both
PET and MRI.
Summary and Outlook
It is safe to say that personalised
healthcare and molecular imaging go
hand-in-hand. Economic and social pres-
sures mean that early-stage validation of
drug efficacy is crucial in clinical trials,
and in assessing response in patients re-
using intrinsically labelled
68/69
Ge nanopar-
ticles,
[71]
synthesis of dextran-coated
64
Cu-
doped iron oxide nanoparticles,
[72]
64
Cu-
labelled quantum dots,
[73]
CuS sulphide
nanoparticles,
[74]
Au nanorods,
[75]
MoS
2
nanosheets
[76]
and various
89
Zr-labelled
compounds.
[77–80]
Recent work has also
demonstrated intrinsic labelling of silica
particles with a range of metal radionu-
clides.
[81,82]
In many of these reports, the
researchers highlighted that these agents
showed promise for use in PET and/or du-
al-modality PET/MRI imaging. However,
most of these approaches lack generality or
have important drawbacks when labelling
pre-fabricated nanoparticles.
[83]
To address the challenges of radiolabel-
lingpre-fabricatednanoparticles,wedevel-
oped a novel, heat-induced, chelate-free la-
belling reaction.
[83]
Remarkably, we found
that metal ions in various oxidation states
and taken from across the p-, d- and f-block
quent radiolabelling via a prosthetic group
(e.g. use of [
18
F]-SFB, or ligand conjuga-
tion followed by radiometal chelation).
Labelling the nanoparticle coating can
be accomplished by using similar direct
methods, prosthetic group chemistry, or
metal complexation strategies.
[64,68,69]
Particle- or surface-specific reactions
have only recently been exploited for ra-
diolabelling. In 2014, Goel et al. noted the
importance of the emerging area of intrin-
sically labelled nanoparticles.
[70]
A hand-
ful of articles have now reported the use
of particle-specific chemical reactions to
radiolabel nanoparticles without the use of
a chelate or prosthetic group. In their pio-
neering work on chelate-free radiochemis-
try, Chen et al. reported labelling USPIO
particles with arsenic radionuclides via a
surface-specific reaction.
[67]
Other exam-
ples include the development of USPIO-
based multi-modality PET/MRI agents
Fig. 9. Chemical scope of
18
F-radiolabelling methods used in current preclinical and clinical syntheses. Note: the figure is not intended to be a
comprehensive. The examples presented highlight some of the modern techniques employed by the radiochemical community in synthesising PET
radiotracers.
Fig. 10. Chemical approaches for labelling the surface or coating of nanoparticles.
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ceiving approved therapies. The gamut of
‘-omic’ technologies provide valuable in
vitro data that complements classical IVDx
tools. MDx methods are analogous to tak-
ing photographic snapshots – they provide
high-resolution data and can characterise
many biomarkers simultaneously, but have
inherent limitations measuring spatial and
temporal dynamics. On the other hand,
molecular imaging offers the advantage
of measuring lesion-specific, spatial and
temporal changes in throughout the whole
body, but is often limited to the detection
of a single biomarker. Nevertheless, the ex-
amples presented here highlight the power
of using imaging to correlate changes in
oncogenic signalling pathways with tar-
get-specific therapies. The stage is now set
for combining ‘-omic’ technologies with
molecular imaging tools for exploiting
disease-specific signatures in cancer and
beyond. In addition, combined imaging
modalities like PET/MRI will advance our
understanding of pathobiology and phar-
macogenomics. For radiochemists, the
challenge remains to identify new chemi-
cal reactions and develop radiotracers that
maximise the information available from
functional molecular imaging.
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